Latest news

• JCVI recommends autumn COVID-19 vaccine booster for those at highest risk

  After high uptake for the initial booster dose in December 2021, further uptake has been low. ... NHS. "That is why we have advised planning for further booster vaccines for persons at higher risk of serious illness through an autumn booster programme

• Sanofi/GSK’s next-generation COVID-19 booster granted EC approval

  Two trials compared the immune response induced by VidPrevtyn Beta with approved vaccines. ... This was based on positive results from two ‘immunobridging' trials comparing the immune response induced by Sanofi/GSK’s new booster with currently

• Pfizer/BioNTech’s second bivalent COVID-19 booster approved by MHRA

  All approved COVID-19 booster vaccines help to improve the protection obtained from earlier doses of the vaccine and help give longer-term protection against getting seriously ill from COVID-19. ... For the UK autumn booster campaign, the MHRA advises

• JCVI publishes advice on COVID-19 vaccines ahead of autumn booster campaign

  The Joint Committee on Vaccination and Immunisation (JCVI) has published its advice on which COVID-19 vaccines should be used in this year’s autumn booster programme. ... Professor Wei Shen Lim, chair of COVID-19 immunisation on the JCVI, said: "All of

• Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine

  Preliminary laboratory studies show both vaccines neutralise Omicron BA.4 and BA.5. ... The data shows that a booster dose of both Omicron-adapted vaccines gave a considerably higher immune response against Omicron BA.1, compared to Pfizer/BioNTech’s